Lipid nanoparticle (LNP) mRNA vaccines emerged during the COVID-19 pandemic to form an almost miraculous protection against a virus, which killed millions around the world. Aided by expedited ...

Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Randall ...

Marama Labs has launched its CloudSpec instrument for nanomedicine development, which is expected to cut time and speed up ...

Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, "Shin-Etsu Chemical") and Hokkaido University (Location ...

“The lipid nanoparticles have evolved to significantly ... infectious pathogens or treat cancer and autoimmune disease. mRNA LNP would allow the body to produce the antibodies directly, thus ...

The nanoparticle is effectively the vehicle that sends the mRNA into your cells ... breaking the bottleneck in the LNP market that is expected to grow seven-fold in the next decade.

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...